RE:RE:RE:RE:RE:RE:Novartis US$2.9 Billion MorphoSys BET Inhibitor safety issueMost colorectal cancer (CRC) patients are insensitive to immune checkpoint inhibitors (ICIs) due to the immunosuppressive tumor microenvironment (TME). Epigenetic factors such as the bromo-and extraterminal domain (BET) family proteins may be responsible for the immunosuppressive microenvironment. Previous studies have shown that inhibitors of BET family proteins have the potential to remodel the immunosuppressive TME.
This demonstrates that Big Pharma is significantly interested in remodeling the cancer cell TME and the upregulation of CD8+ T cells (TiLs -> NK and dendretic cells) that ONCY's pelareorep has is proving to be effective in doing.
In spite of Big Pharma forging into this space Novartis/MorphoSys BET inhibitor has proved to have safety issues that has slowed its development of this class of inhibitors in the treatment of cancer. They will soon realize that ONCY's pelareorep is their only prudent alternative, particular in combination with PD-L1 checkpoint inhibitors, CAR-T, ADCs, bispecifics, and small molecules, such as CDK4 and PARP inhibitors.